Author

Michael J. Emch

Mayo ClinicORCID 0000-0001-8670-8138Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1

Frequent Co-Authors

John R. HawseiD· 2 shared Adam D. BassiD· 1 shared Archit Bajaj· 1 shared August J. JohniD· 1 shared Bibekananda KariD· 1 shared Brandon W. SimoneiD· 1 shared Carla M. ManniD· 1 shared Cristina CorreiaiD· 1 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

John R. HawseORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistryiSciencePeer-reviewedMay 1, 2026

Unbiased CRISPR Synthetic Lethal Screening for Genetic Vulnerabilities in Succinate Dehydrogenase (SDH)-loss Model of Paraganglioma

Fatimah J. Al Khazal, Michael J. Emch, Cristina Correia…·Louis James Maher III

The paper uses CRISPR screening to identify genetic vulnerabilities in SDH-deficient paraganglioma cells, finding the neddylation pathway as a potential therapeutic target.

DOI 10.1016/j.isci.2026.115885

mousegenetic perturbation / CRISPR

𝕏 PostBluesky

Cancer Biologynpj Precision OncologyPeer-reviewedJul 11, 2025

Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer

Esther P. B. Rodman, Michael J. Emch, Xiaonan Hou…·John R. Hawse

This study identifies lestaurtinib as a potent inhibitor of ovarian cancer, effective against resistant models, by targeting JAK/STAT signaling and synergizing with standard therapies.

8 citations

humanbulk RNA-seq

𝕏 PostBluesky

GeneticsThe CRISPR JournalPeer-reviewedDec 1, 2019

Expanding The CRISPR Toolbox With Mad7 In Zebrafish And Human Cells

Wesley A. Wierson, Brandon W. Simone, Zachary WareJoncas…·Jeffrey J. Essner

This paper characterizes ErCas12a, a new CRISPR/Cas system, showing it enables efficient DNA repair and gene integration in zebrafish and human cells.

59 citations

zebrafishhuman

𝕏 PostBluesky